14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
QNRX vs REVB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Revelation Biosciences, Inc. (REVB) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). QNRX carries a Unified Composite Score of 47.1/100 (HOLD) at $3.36 (N/M Forward P/E, 0.0% operating margin), whereas REVB carries 43.7/100 (HOLD) at $3.69 (0.9x Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While QNRX currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. REVB 43.7/100 HOLD), REVB captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.8); meanwhile REVB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QNRX vs REVB. Trailing 12-month operating profitability (QNRX 0.0% vs REVB 0.0%) and valuation multiples (QNRX N/M vs REVB 0.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.1M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ QNRX vs REVB Key Questions & Quantitative Answers
As of Nov 19, 2026, Revelation Biosciences, Inc. (REVB) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). QNRX carries a Unified Composite Score of 47.1/100 (HOLD) at $3.36 (N/M Forward P/E, 0.0% operating margin), whereas REVB carries 43.7/100 (HOLD) at $3.69 (0.9x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While QNRX currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. REVB 43.7/100 HOLD), REVB captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.8); meanwhile REVB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
QNRX leads the Growth & Scale pillar: QNRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with REVB at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, QNRX generates N/A in USD-normalized revenue versus N/A for REVB. In operating R&D and SG&A reinvestment, QNRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for REVB.
REVB screens cheaper on headline valuation multiples. QNRX trades at N/M Forward P/E, 8.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas REVB trades at 0.9x Forward P/E, 0.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against QNRX (-142.6% ROE) versus REVB (-133.4% ROE) capital efficiency.
In options market volatility and institutional positioning, QNRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 72% Vol realized risk). By comparison, REVB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.90β · 101% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.